Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Gilead Sciences Inc (GILD) reports robust sales growth, driven by HIV and oncology advancements, despite challenges from ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company ...

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.